非小细胞肺癌患者血清RCAS1水平检测临床意义分析

Clinical significance of detection of serum RCAS1 levels in non-small cell lung cancer

目的:探讨非小细胞肺癌(NSCLC)患者血清SiSo细胞表达的受体结合肿瘤抗原(RCAS1)水平及其临床意义。方法:采用酶联免疫吸附法(ELISA)定量检测102例NSCLC患者和40例良性肺部疾病患者血清RCAS1水平,并以35名正常人血清作为对照,比较不同分期、有无转移及术后1年复发与否的患者之间是否存在差异。结果:NSCLC组血清RCAS1水平〔(48.6±18.5)U/mL〕显著高于健康对照组〔(13.5±11.8)μg/mL;t=7.56,P=0.000〕和良性肺部疾病组〔(18.3±14.8)μg/mL;t=3.73,P=0.001〕。Ⅲ/Ⅳ期患者血清RCAS1水平〔(60.8±16.3)U/mL〕显著高于Ⅰ/Ⅱ期患者〔(34.6±15.3)U/mL;t=3.56,P=0.000〕。有转移患者和术后1年内复发患者血清RCAS1水平〔(58.3±16.9)、(59.6±14.9)U/mL〕分别高于无转移患者和无复发患者〔(35.6±13.2)、(33.8±13.6)U/mL〕,P值分别为0.002、0.001。结论:NSCLC患者血清RCAS1表达水平有可能作为肿瘤转移和术后复发的预测指标。

OBJECTIVE：To investigate serum receptor-binding cancer antigen expressed on SiSo cells （RCAS1） lev els in non-small cell lung cancer （NSCLC）and its clinical significance. METHODS： Patients with NSCI.C （n= 102）and be nigh lung disease （n=40） and healthy controls （n=35）were recruited into this study. Serum RCAS1 levels were measured using enzyme-linked immunosorbent assays （ELISA）. The results were compared between patients with different tumor stages,metastasis status,and postoperative recurrence 1 year after surgery. RESULTS： Patients with NSCLC bad higher RCAS1 levels [（48.6＋18.5） U/mL]than that of the benign lung disease [（18.3_＋ 14.8） ug/mL;t= 3. 73,P=0. 001] and the healthy group [（13.5＋ 11.8） ug/mL;t=7.56,P=0. 000]. Serum RCAS1 levels in stageIII/IVpatients E（60.8±16.3） U/roLl were significantly higher than that of stage I / lI patients [（34.6±15.3） U/mL;t：3.56,P=0. 000]. Ser- um RCAS1 levels were higher in patients with distant metastasis or postoperative recurrence [（ 58. 3 ± 16. 9） U/rnL, （59.6±14.9） U/mL]than those without them （35. 6＋ 13.2） U/mL, （33.8± 13.6） U/mL,t= 3.47, P= 0. 002;t = 5.83,P=0. 0011. CONCLUSION： Serum RCAS1 level in patients with NSCLC could be a useful marker for metastasis and postoperative recurrence.